SG11201803565UA - Cd131 binding proteins and uses thereof - Google Patents
Cd131 binding proteins and uses thereofInfo
- Publication number
- SG11201803565UA SG11201803565UA SG11201803565UA SG11201803565UA SG11201803565UA SG 11201803565U A SG11201803565U A SG 11201803565UA SG 11201803565U A SG11201803565U A SG 11201803565UA SG 11201803565U A SG11201803565U A SG 11201803565UA SG 11201803565U A SG11201803565U A SG 11201803565UA
- Authority
- SG
- Singapore
- Prior art keywords
- victoria
- parkville
- international
- csl limited
- poplar
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108091008324 binding proteins Proteins 0.000 title 1
- 108010063738 Interleukins Proteins 0.000 abstract 3
- 102000015696 Interleukins Human genes 0.000 abstract 3
- 241000219000 Populus Species 0.000 abstract 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108010002616 Interleukin-5 Proteins 0.000 abstract 1
- 240000007594 Oryza sativa Species 0.000 abstract 1
- 235000007164 Oryza sativa Nutrition 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000009566 rice Nutrition 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 1 June 2017 (01.06.2017) WIPOIPCT (10) International Publication Number WO 2017/088028 A1 (51) International Patent Classification: C07K16/00 (2006.01) A61P 37/00 (2006.01) A61K39/395 (2006.01) (21) International Application Number: PCT/AU2016/051158 (22) International Filing Date: (25) Filing Language: (26) Publication Language 25 November 2016 (25.11.2016) English English (30) Priority Data: 2015904924 27 November 2015 (27.11.2015) AU (71) Applicant: CSL LIMITED [AU/AU]; 45 Poplar Road, Parkville, Victoria 3052 (AU). (72) Inventors: OWCZAREK, Catherine; c/o CSL Limited, 45 Poplar Road, Parkville, Victoria 3052 (AU). PANOUS- IS, Kosta; c/o CSL Limited, 45 Poplar Road, Parkville, Victoria 3052 (AU). WILSON, Nicholas; c/o CSL Lim ited, 45 Poplar Road, Parkville, Victoria 3052 (AU). HARDY, Matthew; c/o CSL Limited, 45 Poplar Road, Parkville, Victoria 3052 (AU). EDWARDS, Kirsten; c/o CSL Limited, 45 Poplar Road, Parkville, Victoria 3052 (AU). RAYZMAN, Veronika; c/o CSL Limited, 45 Poplar Road, Parkville, Victoria 3052 (AU). (74) Agent: FB RICE; Level 14, 90 Collins St, Melbourne, Victoria 3000 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) < 00 oo 00 n O (54) Title: CD131 BINDING PROTEINS AND USES THEREOF (57) : The present disclosure provides a CD131-binding protein comprising an antigen binding domain of an antibody, wherein the antigen binding domain binds to or specifically binds to CD131 and neutralizes signaling by interleukin (IL) 3, IL-5 and granulocyte-macrophage colony stimulating factor (GM-CSF), and uses thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015904924A AU2015904924A0 (en) | 2015-11-27 | Cd131 binding proteins and uses thereof | |
| PCT/AU2016/051158 WO2017088028A1 (en) | 2015-11-27 | 2016-11-25 | Cd131 binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201803565UA true SG11201803565UA (en) | 2018-06-28 |
Family
ID=58762858
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201803565UA SG11201803565UA (en) | 2015-11-27 | 2016-11-25 | Cd131 binding proteins and uses thereof |
| SG10201912051TA SG10201912051TA (en) | 2015-11-27 | 2016-11-25 | Cd131 binding proteins and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912051TA SG10201912051TA (en) | 2015-11-27 | 2016-11-25 | Cd131 binding proteins and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10894834B2 (en) |
| EP (1) | EP3380514A4 (en) |
| JP (1) | JP6882287B2 (en) |
| KR (1) | KR20180084134A (en) |
| CN (2) | CN108368167B (en) |
| AU (1) | AU2016361462B2 (en) |
| BR (1) | BR112018010766A8 (en) |
| CA (1) | CA3003200A1 (en) |
| HK (1) | HK1253533A1 (en) |
| IL (1) | IL259519B (en) |
| MX (1) | MX2018006410A (en) |
| SG (2) | SG11201803565UA (en) |
| WO (1) | WO2017088028A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201803565UA (en) * | 2015-11-27 | 2018-06-28 | Csl Ltd | Cd131 binding proteins and uses thereof |
| CN108586606A (en) * | 2018-04-24 | 2018-09-28 | 上海药明生物技术有限公司 | One kind is for removing endotoxic method in antibody protein |
| WO2022115914A1 (en) * | 2020-12-04 | 2022-06-09 | Csl Innovation | Methods for treating inflammatory skin conditions |
| EP4262872A1 (en) * | 2020-12-21 | 2023-10-25 | CSL Innovation Pty Ltd | Methods for treating or preventing acute respiratory distress syndrome |
| JPWO2023027177A1 (en) * | 2021-08-26 | 2023-03-02 | ||
| WO2023173173A1 (en) * | 2022-03-16 | 2023-09-21 | CSL Innovation Pty Ltd | Method of treating an eosinophil-associated disease |
| WO2023192944A1 (en) * | 2022-04-01 | 2023-10-05 | The Jackson Laboratory | Combination immune checkpoint inhibitor therapies |
| WO2024081996A1 (en) * | 2022-10-20 | 2024-04-25 | CSL Innovation Pty Ltd | Method of treating severe asthma |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP525198A0 (en) | 1998-08-13 | 1998-09-03 | Medvet Science Pty. Ltd. | Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof |
| WO2000047620A1 (en) * | 1999-02-08 | 2000-08-17 | Medvet Science Pty Ltd | Cytokine-binding domain |
| JP2005538682A (en) | 2001-12-03 | 2005-12-22 | アブジェニックス・インコーポレーテッド | Antibody against carboxic anhydrase IX (CAIX) tumor antigen |
| EP1467757B1 (en) | 2001-12-28 | 2008-05-07 | Amgen Fremont Inc. | Use of antibodies against the muc18 antigen |
| AU2005251764A1 (en) | 2004-06-04 | 2005-12-22 | Genentech, Inc. | Method for treating lupus |
| WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
| WO2007147019A2 (en) | 2006-06-13 | 2007-12-21 | Zymogenetics, Inc. | Il-17 and il-23 antagonists and methods of using the same |
| WO2013090989A1 (en) | 2011-12-22 | 2013-06-27 | Csl Limited | Method of treating inflammatory bowel disease |
| SG11201803565UA (en) * | 2015-11-27 | 2018-06-28 | Csl Ltd | Cd131 binding proteins and uses thereof |
-
2016
- 2016-11-25 SG SG11201803565UA patent/SG11201803565UA/en unknown
- 2016-11-25 JP JP2018526904A patent/JP6882287B2/en active Active
- 2016-11-25 SG SG10201912051TA patent/SG10201912051TA/en unknown
- 2016-11-25 CN CN201680069441.4A patent/CN108368167B/en active Active
- 2016-11-25 US US15/779,252 patent/US10894834B2/en active Active
- 2016-11-25 BR BR112018010766A patent/BR112018010766A8/en active Search and Examination
- 2016-11-25 WO PCT/AU2016/051158 patent/WO2017088028A1/en active Application Filing
- 2016-11-25 MX MX2018006410A patent/MX2018006410A/en unknown
- 2016-11-25 KR KR1020187017798A patent/KR20180084134A/en not_active Application Discontinuation
- 2016-11-25 CN CN202311005982.9A patent/CN116987190A/en active Pending
- 2016-11-25 AU AU2016361462A patent/AU2016361462B2/en active Active
- 2016-11-25 CA CA3003200A patent/CA3003200A1/en active Pending
- 2016-11-25 EP EP16867461.2A patent/EP3380514A4/en active Pending
-
2018
- 2018-05-22 IL IL259519A patent/IL259519B/en unknown
- 2018-10-05 HK HK18112733.7A patent/HK1253533A1/en unknown
-
2020
- 2020-11-20 US US16/953,499 patent/US11840573B2/en active Active
-
2023
- 2023-10-30 US US18/497,461 patent/US20240174757A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018006410A (en) | 2019-01-31 |
| IL259519B (en) | 2022-06-01 |
| AU2016361462A1 (en) | 2018-05-10 |
| SG10201912051TA (en) | 2020-02-27 |
| AU2016361462B2 (en) | 2023-09-21 |
| US11840573B2 (en) | 2023-12-12 |
| US20190062438A1 (en) | 2019-02-28 |
| WO2017088028A1 (en) | 2017-06-01 |
| JP6882287B2 (en) | 2021-06-02 |
| KR20180084134A (en) | 2018-07-24 |
| CN116987190A (en) | 2023-11-03 |
| RU2018123349A3 (en) | 2020-05-26 |
| BR112018010766A8 (en) | 2019-02-26 |
| EP3380514A4 (en) | 2019-05-22 |
| JP2019500859A (en) | 2019-01-17 |
| CN108368167A (en) | 2018-08-03 |
| CA3003200A1 (en) | 2017-06-01 |
| US10894834B2 (en) | 2021-01-19 |
| CN108368167B (en) | 2023-09-05 |
| EP3380514A1 (en) | 2018-10-03 |
| RU2018123349A (en) | 2019-12-27 |
| HK1253533A1 (en) | 2019-06-21 |
| BR112018010766A2 (en) | 2018-11-21 |
| US20210324091A1 (en) | 2021-10-21 |
| IL259519A (en) | 2018-07-31 |
| US20240174757A1 (en) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201803565UA (en) | Cd131 binding proteins and uses thereof | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201810640RA (en) | Cd33 specific chimeric antigen receptors | |
| SG11201810509PA (en) | Anti-pd-l1 antibodies | |
| SG11201809625RA (en) | 1-tetrahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201810591VA (en) | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen | |
| SG11201805532XA (en) | Multivalent and multispecific 41bb-binding fusion proteins | |
| SG11201901307VA (en) | Heterodimeric immunoglobulin constructs and preparation methods thereof | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201805420SA (en) | Antibodies and conjugates thereof | |
| SG11201807794VA (en) | Naphthene-containing distillate stream compositions and uses thereof | |
| SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201407644UA (en) | Methods for making fully human bispecific antibodies using a common light chain | |
| SG11201908456VA (en) | Linker units and molecular constructs comprising same | |
| SG11201901172QA (en) | A method for manufacturing a fuel component |